Compass Therapeutics Inc (CMPX) — 13F Filings Explorer (Q2 2026)

CMPX ranks #2808 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

217 institutions disclose a position in CMPX, but none treat it as a major bet — even Enavate Sciences GP, LLC, its most concentrated holder, allocates just 4.9% of its own portfolio to it.

Independent Financial Group, LLC has trimmed its CMPX position for two straight quarters, cutting it by $96.8K while still holding $23.7K.

CMPX is down 4.1% today, but institutions show net buying of $61.4M this quarter — a divergence between today's price move and the underlying institutional flow.

CMPX reported a net loss of $66.5M in its latest fiscal year.

• Not yet profitable — net loss of $66.5M in the latest fiscal year
• Revenue declined 100.0% year over year
• Net income declined year over year, from -$49.4M to -$66.5M
• Operating cash flow was negative, using $49.1M in cash
• Current ratio of 15.02x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.12x equity — within a conventional range